/A
Phase 1
- Conditions
- MedDRA version: 20.0Level: LLTClassification code 10062893Term: RhizarthrosisSystem Organ Class: 100000004859Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
- Registration Number
- EUCTR2017-002298-20-FR
- Lead Sponsor
- Centre Hospitalier Départemental Vendée
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 60
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 90
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by the intervention in the EUCTR2017-002298-20-FR Phase I rhizarthrosis trial?
How does the intervention in EUCTR2017-002298-20-FR compare to corticosteroid injections for rhizarthrosis pain management?
Which biomarkers predict response to novel anti-inflammatory agents in the Centre Hospitalier Départemental Vendée Phase I rhizarthrosis trial?
What are the safety profiles of novel anti-inflammatory agents in Phase I rhizarthrosis trials?
Are there combination therapies involving IL-1 inhibitors or MMP inhibitors being tested for rhizarthrosis in early-phase trials?